The stereoselective κ-opioid receptor antagonist Mr 2266 does not exhibit stereoselectivity as an antagonist at the orphan opioid (ORL1) receptor

被引:0
|
作者
U. Bauer
M. Nakazi
M. Kathmann
M. Göthert
E. Schlicker
机构
[1] Institut für Pharmakologie und Toxikologie,
[2] Universität Bonn,undefined
[3] Reuterstrasse 2b,undefined
[4] D-53113 Bonn,undefined
[5] Germany e-mail: e.schlicker@uni-bonn.de,undefined
[6] Fax: +49-228-735404,undefined
关键词
Key words κ-opioid receptor; ORL1 receptor; Nociceptin; U-69; 593; Mr 2266; Mr 2267; Noradrenaline release; Mouse and guinea-pig brain; cortex;
D O I
暂无
中图分类号
学科分类号
摘要
Mr 2266 [(-)-(1R,5R,9R)-5,9-diethyl-2-(3-furylmethyl)-2’-hydroxy-6,7-benzomorphan] is an antagonist at κ-opioid receptors and at ORL1 receptors as well. The aim of our study was to examine whether the known stereoselective antagonism of Mr 2266 at κ-opioid receptors also extends to ORL1 receptors. In mouse brain cortex membranes, the binding of the ORL1 receptor agonist [3H]nociceptin was equipotently inhibited by Mr 2266 and its enantiomer Mr 2267 (pKi 4.82 and 5.14, respectively), whereas the binding of the κ-opioid receptor agonist [3H]U-69,593 was inhibited by Mr 2266 more potently (pKi 9.11) than by its enantiomer Mr 2267 (pKi 7.15). In mouse brain cortex slices preincubated with [3H]noradrenaline, the concentration-response curve of nociceptin for inhibition of the electrically evoked overflow of tritium was equipotently shifted to the right by Mr 2266 and Mr 2267 (pA2 5.77 and 5.64, respectively). On the other hand, the inhibitory effect of U-69,593 on the electrically evoked overflow of tritium in guinea-pig brain cortex slices preincubated with [3H]noradrenaline was more potently antagonized by Mr 2266 (pA2 8.81) than by Mr 2267 (pA2 7.15). These data show that the stereoselective antagonism of Mr 2266 at κ-opioid receptors does not extend to ORL1 receptors.
引用
收藏
页码:17 / 20
页数:3
相关论文
共 50 条
  • [31] The bovine pineal gland contains delta and mu but not kappa or ORL1 opioid receptor subtypes
    Govitrapong, P
    Sawlom, S
    Chetsawang, B
    Sangchot, P
    Ebadi, M
    PROCEEDINGS OF THE FORTY-FIFTH ANNUAL MEETING OF THE WESTERN PHARMACOLOGY SOCIETY, 2002, 45 : 32 - 35
  • [32] RECOGNITION OF OPIOID AGONIST AND ANTAGONIST IN THE OPIOID RECEPTOR-BINDING SITE
    NOZAKI, M
    NIWA, M
    HASEGAWA, J
    IMAI, E
    HORI, M
    FUJIMURA, H
    LIFE SCIENCES, 1982, 31 (12-1) : 1339 - 1342
  • [33] Nociceptin and the ORL1 receptor: Pharmacology of a new opioid receptor [Nociceptin und der ORL1-rezeptor: Pharmakologie eines neuen opioidrezeptors]
    Grond S.
    Meuser T.
    Pietruck C.
    Sablotzki A.
    Der Anaesthesist, 2002, 51 (12) : 996 - 1005
  • [34] In Silico Study of the Structurally Similar ORL1 Receptor Agonist and Antagonist Pairs Reveal Possible Mechanism of Receptor Activation
    Sencanski, Milan
    Dosen-Micovic, Ljiljana
    PROTEIN JOURNAL, 2014, 33 (03): : 231 - 242
  • [35] Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide
    Shimohigashi, Y
    Hatano, R
    Fujita, T
    Nakashima, R
    Nose, T
    Sujaku, T
    Saigo, A
    Shinjo, K
    Nagahisa, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (39) : 23642 - 23645
  • [36] Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy μ opioid receptor agonist and a δ opioid receptor antagonist
    Mada, Sanjana
    Gerak, Lisa R.
    Soyer, Amelie
    Maguire, David R.
    Hu, Zehua
    Minervini, Vanessa
    Cunningham, Christopher W.
    France, Charles P.
    PSYCHOPHARMACOLOGY, 2020, 237 (12) : 3591 - 3602
  • [37] Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist
    Sanjana Mada
    Lisa R. Gerak
    Amélie Soyer
    David R. Maguire
    Zehua Hu
    Vanessa Minervini
    Christopher W. Cunningham
    Charles P. France
    Psychopharmacology, 2020, 237 : 3591 - 3602
  • [38] MODULATION OF APPETITIVELY AND AVERSIVELY MOTIVATED BEHAVIOR BY THE KAPPA-OPIOID ANTAGONIST MR2266
    FANSELOW, MS
    CALCAGNETTI, DJ
    HELMSTETTER, FJ
    BEHAVIORAL NEUROSCIENCE, 1989, 103 (03) : 663 - 672
  • [39] An opioid receptor antagonist, naltrexone, does not alter taste and smell responses in humans
    Scinska, A
    Koros, E
    Polanowska, E
    Kukwa, A
    Bogucka-Bonikowska, A
    Kostowski, W
    Habrat, B
    Bienkowski, P
    POLISH JOURNAL OF PHARMACOLOGY, 2000, 52 (05): : 397 - 402
  • [40] ORL-1 opioid receptor expression in inflammation
    Stamer, UM
    Eggert, C
    Stüber, F
    INTENSIVE CARE MEDICINE, 2002, 28 : S16 - S16